CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more


News and features about the latest developments in optics with a focus on industry

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Scottish biotechnology company aims to improve glaucoma surgery outcomes

New research suggests that an artificial virus could provide a more targeted and less toxic option for glaucoma surgery


A Scottish biotechnology company has reported that a new gene therapy technology improves outcomes of glaucoma surgery.

The research, which was published in Molecular Therapy, described the use of NanoGenics’ LipTide technology.

LipTide is a peptide-based nanoparticle that can be modified to target different cell types.

The technology addresses a current pitfall in glaucoma surgery where a tiny whole inserted in the base of the eye closes through the body’s own healing mechanisms.

This natural process means that the traditional trabeculectomy procedure fails half of the time.

Cytotoxic agents are used to prevent the hole from closing but these drugs have a poor safety profile.

The new study found that when used in animals, LipTide produces the same effect as cytotoxic agents with reduced scarring and no side effects.